

POSTER NUMBER 7

Lu-177 DOTATATE therapy for inoperable or progressive mid-gut NET

Yahya T¹, Garg G¹, Singh J¹, Paul P¹, Abramson S¹, Taoudi M¹, Akamnonu O¹,
Berger M¹, Abraham T¹, Wolin E², Milstein D¹ & Love C¹.

¹Division of Nuclear Medicine, ²Neuroendocrine Specialty Group
Montefiore Medical Center, Bronx, NY

Introduction: Therapy with beta emitter Lu-177 DOTATE recently underwent evaluation for patients with inoperable or progressive mid-gut neuroendocrine tumors (NET) in this country and was found to be safe and effective long-term therapy. An expanded access approved by FDA has allowed our institution to offer this therapy for patients with inoperable NET or progressive disease despite Octreotide therapy. This presentation summarizes the steps necessary to bring this therapy to clinical use at our institution and the challenges that we faced so that others will know what to expect should this therapy be made available in their institution. After reading this presentation, the reader will learn the following:

1. Nature and preparation for Lu-177 therapy
2. Various federal, city and institutional processes and requirements before it can be made available locally
3. Logistics for drug delivery and infusion
4. Patient's side effects